Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to a 22% weight reduction in obese and overweight patients compared to a 2.0% weight gain in the placebo group. The trial showed promising results for amycretin, a treatment that targets the same gut and pancreas hormones as Novo Nordisk’s flagship obesity drug Wegovy and diabetes treatment Ozempic. Novo Nordisk is also developing an amycretin obesity pill, with early-stage trials demonstrating a 13.1% weight loss after 12 weeks and mild-to-moderate side effects.
Full Article
Tim Dolighan cartoon, March 10, 2025
Tim Dolighan's cartoon from March 10, 2025, is featured in the article. The video failed to load, but readers can access other videos from the team by refreshing their browser. The cartoon likely includes humorous or satirical content related to current events or popular culture. Full Article
Read more